Bloomage BioTechnology (688363) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2026 was RMB 1.76 billion, down 22.32% year-over-year, mainly due to a decline in skin science innovation business income.

• Net profit attributable to shareholders was RMB 153 million, a decrease of 30.82% year-over-year.

• Gross margin remained high at 67.96%.

• The company continued to invest in R&D, with R&D expenses accounting for 12.07% of revenue.

• Strategic focus on AI and synthetic biology, with significant progress in digital transformation and product innovation.

Financial highlights

• Operating income: RMB 1,756 million, down 22.32% year-over-year.

• Net profit: RMB 153 million, down 30.82% year-over-year.

• Operating cash flow: RMB 524 million, up 140.08% year-over-year.

• Basic and diluted EPS: RMB 0.32, down 30.43% year-over-year.

• Net assets attributable to shareholders: RMB 7,090 million, up 0.07% from year-end 2025.

• Total assets: RMB 8,881 million, up 2.17% from year-end 2025.

Outlook and guidance

• The company is focused on quality growth, digital transformation, and expanding its global presence.

• Continued investment in R&D and AI-driven innovation expected to drive future growth.

• Management expects ongoing challenges from international market volatility and domestic demand recovery.